News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Invitation to Presentation of Egetis’ Third Quarter 2024 Report

November 5, 2024

Stockholm, Sweden, November 5, 2024. Egetis Therapeutics AB (publ) (NASDAQ Stockholm: EGTX) today announced that it will publish its third quarter 2024 report on Friday, November 8, 2024, at 07:00 am CET. Egetis will also host a conference call the same day at 10:00 am CET to discuss the third quarter 2024 financial results and recent corporate progress.
 
If you wish to participate via webcast, please use the link below. You can ask written questions via the webcast.
https://ir.financialhearings.com/egetis-therapeutics-q3-report-2024/register  

If you wish to participate via teleconference, please register via the link below. After registration you will be provided with phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference. 
https://conference.financialhearings.com/teleconference/?id=5003940

The conference call will be made available on the Company’s website after the call.

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]